On Thursday, Monsanto Company (MON)’s shares declined -0.56%, and closed at $116.30, as with half its fiscal year complete, the company highlighted continued progress on several key milestones related to its long-term growth drivers, counting the strong performance of Intacta RR2 PRO™ soybeans in their second year of commercialization, advancement of pre-commercial activities for Roundup Ready 2 Xtend™ soybeans and the continued footprint expansion of its global corn business, even against a smaller acreage base, as farmers embrace the latest innovations. The corporation also noted its estimates for fiscal year 2015 earnings per share and free cash flow remain in the ranges of its original guidance though now trending at the lower end of the ranges given the industry-wide headwinds of declining corn acres and the strengthening of the U.S. dollar.
Net sales for the fiscal year 2015 second quarter reduced over the preceding year’s second quarter to about $5.2 billion, with gross profit for the quarter also decreasing over the preceding year period to $3 billion. For the first six months, net sales were about $8.1 billion and gross profit about $4.5 billion.
The second quarter results were aligned with the corporation’s guidance, with its performance reflecting in part the formerly outlined predictable shift in gross profit from the U.S. Channel® seed brand business of about $275 million from the second quarter to the third quarter. This was balanced against strong soybean performance in South America and the United States. In Agricultural Productivity, the decline in gross profit was primarily volume related, as the corporation continued to convert from non-branded to branded volumes of Roundup®, which is shifting gross profit to the second half to support key application windows for over-the-top sprays.
Selling, general and administrative (SG&A) costs were $647 million and R&D expenses were $372 million for the second quarter. Continued disciplined reductions in the base spend led to a slight decline in total operating expenses while still allowing for raised spend in the corporation’s Climate and biological platforms to support the long-term growth prospects for these opportunities.
The corporation’s second quarter earnings per share (EPS) was $2.90 on an ongoing basis and $2.92 on an as-stated basis, within the ranges outlined during the first quarter. EPS for the first six months of fiscal year 2015 was $3.36 on an ongoing basis and $3.41 on an as-stated basis.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds comprising of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.
Analog Devices, Inc. (NASDAQ:ADI)’s shares dropped -0.53%, and settled at $62.24, during the last trading session on Thursday.
Analog Devices, introduced a quad-channel, 2.4-GSPS, 16-bit D/A converter with industry leading dynamic range performance in the 100- to 300-MHz band for complex IF transmitters. The highly integrated AD9154 quad, 16-bit D/A converter is the only device of its kind to comprise an on-chip PLL (phase-locked loop) and eight-lane JESD204B interface. The combination of features allows designers to use a single device to meet all of their requirements in multicarrier GSM and LTE transmitters designed for wireless macro base stations, point-to-point microwave radio, military radios and radio test equipment. The new converter comprises a range of features optimized for complex IF (intermediate frequency) transmit applications, counting complex digital modulation, input-signal power detection, and gain, phase and offset compensation.
AD9154 Key Features:
- Single-carrier LTE 20-MHz bandwidth ACLR = 76.7 dBC at 180-MHz IF.
- Six-carrier GSM IMD = 78-dBC, 600-kHz carrier spacing at 180-MHz IF.
- SFDR = 72-dBC at 180-MHz IF, -6 dBFS.
- 8-lane JESD204B interface..
- Support for quad-DAC or dual-DAC mode.
- Low power: 2.1-W at 1.5 GSPS..
Analog Devices, Inc. engages in the design, manufacture, and marketing of analog, mixed-signal, and digital signal processing integrated circuits (ICs) for use in industrial, automotive, consumer, and communication markets worldwide.
At the end of Thursday’s trade, H&R Block, Inc. (NYSE:HRB)’s shares dipped -0.53%, and closed at $32.15, as According to the world’s largest consumer tax services provider, U.S. expats are filing more tax returns than ever before but there are still millions of them who should be filing. While the filing deadline isn’t until June 15 for U.S. expats, studies show that more than 4 out of 10 still file in March and April, working to beat the typical April 15 deadline. For those U.S. citizens living abroad, they face three primary concerns this tax season: disclosure and streamlined compliance requirements, Affordable Care Act (ACA) changes and the closure of IRS offices abroad.
“Filing a U.S. tax return while living abroad can be a daunting task, especially with a new health care law in effect and changes to the IRS presence overseas,” said Roland Sabates, operations director of H&R Block’s expat filing services.
Bristol-Myers Squibb Company (NYSE:BMY), ended its Thursday’s trading session with -0.52% loss, and closed at $63.23.
Bristol-Myers Squibb Company, will declare results for the first quarter of 2015 on Tuesday, April 28, 2015. During a conference call at 11 a.m. EDT on April 28, corporation executives will review financial information and will address inquiries from investors and analysts.
Bristol-Myers Squibb Corporation discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
